A Study to Evaluate the Efficacy of Propranolol in Boosting Immunotherapy in Hepatocellular Carcinoma, Cholangiocarcinoma and Pancreatic Adenocarcinoma
Latest Information Update: 03 Jul 2025
At a glance
- Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Propranolol (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Liver cancer; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms BLOCKED
Most Recent Events
- 26 Jun 2025 Planned End Date changed from 1 Oct 2028 to 1 Oct 2029.
- 26 Jun 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Oct 2026.
- 11 Jun 2024 Status changed from not yet recruiting to recruiting.